Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Pioglitazone decreases type 2 diabetes risk in stroke patients with insulin resistance

bs_subtitle

First published June 2016, updated March 2022   Pioglitazone greatly decreases the risk of developing type 2 diabetes, especially for those who already have prediabetes and/or who have had strokes, according to a study also presented at the ADA. The Insulin Resistance Intervention after Stroke trial (IRIS) recently found that the thiazolidinedione (TZD) drug, pioglitazone, reduced the risk of fatal and non-fatal stroke and myocardial infarction by 24% in people with cerebrovascular disease. This secondary analysis of the data collected in the IRIS trial examined pioglitazone’s effect on diabetes prevention in a large group of non-diabetic stroke patients with insulin

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy